全文获取类型
收费全文 | 26831篇 |
免费 | 2479篇 |
国内免费 | 815篇 |
专业分类
耳鼻咽喉 | 490篇 |
儿科学 | 776篇 |
妇产科学 | 325篇 |
基础医学 | 6523篇 |
口腔科学 | 190篇 |
临床医学 | 2601篇 |
内科学 | 4735篇 |
皮肤病学 | 433篇 |
神经病学 | 1447篇 |
特种医学 | 621篇 |
外国民族医学 | 17篇 |
外科学 | 2714篇 |
综合类 | 3394篇 |
预防医学 | 1099篇 |
眼科学 | 319篇 |
药学 | 1487篇 |
12篇 | |
中国医学 | 277篇 |
肿瘤学 | 2665篇 |
出版年
2024年 | 19篇 |
2023年 | 443篇 |
2022年 | 605篇 |
2021年 | 1036篇 |
2020年 | 1088篇 |
2019年 | 984篇 |
2018年 | 973篇 |
2017年 | 1011篇 |
2016年 | 1111篇 |
2015年 | 973篇 |
2014年 | 1597篇 |
2013年 | 1996篇 |
2012年 | 1162篇 |
2011年 | 1290篇 |
2010年 | 1005篇 |
2009年 | 979篇 |
2008年 | 1037篇 |
2007年 | 1003篇 |
2006年 | 921篇 |
2005年 | 851篇 |
2004年 | 781篇 |
2003年 | 696篇 |
2002年 | 616篇 |
2001年 | 575篇 |
2000年 | 555篇 |
1999年 | 469篇 |
1998年 | 376篇 |
1997年 | 372篇 |
1996年 | 430篇 |
1995年 | 450篇 |
1994年 | 467篇 |
1993年 | 421篇 |
1992年 | 411篇 |
1991年 | 425篇 |
1990年 | 351篇 |
1989年 | 301篇 |
1988年 | 316篇 |
1987年 | 257篇 |
1986年 | 259篇 |
1985年 | 337篇 |
1984年 | 279篇 |
1983年 | 173篇 |
1982年 | 195篇 |
1981年 | 112篇 |
1980年 | 109篇 |
1979年 | 57篇 |
1978年 | 56篇 |
1977年 | 68篇 |
1976年 | 33篇 |
1974年 | 20篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
翟洪漫 《中国医疗器械信息》2022,(1)
目的:给予不同年龄结节性甲状腺肿合并甲状腺癌患者实施甲状腺超声检查,对相应的超声检查特征展开分析。方法:选择2018年6月~2019年6月的114例患者为对象,所有患者均被确诊为结节性甲状腺肿合并甲状腺癌,并且利用甲状腺二维超声及多普勒超声对患者进行检查,依据患者年龄阶段均分为两组,每组中各纳入57例患者,年龄超过60岁以上的患者为老年组;年龄在60岁以下的患者为中青年组,对比两组患者的血流相关指标与钙化情况数据。结果:老年组中的平均收缩期流速、阻力指数等数据明显低于中青年组,且比较后P<0.05,具有临床可比较意义。老年组中钙化的总例数为21例,总钙化率占比为36.84%,中青年组中钙化的总例数为38例,总钙化率占比为66.67%,前者数据显著低于后者钙化率,P<0.05。结论:在对结节性甲状腺肿合并甲状腺癌患者实施超声检查后,中青年组患者的病灶呈现低回声、高回声以及伴微小钙化、血流分布以内部血流为主、血流阻力大的特点明显高于老年组,能够显著提升诊断效果,为日后的临床治疗提供了图像依据。 相似文献
4.
《Vaccine》2022,40(19):2679-2695
Vaccinations are essential for preventing infectious diseases in children with chronic diseases as they have increased risk of infection from frequent use of biologics. Response to immunizations in this group is not well known.ObjectiveA systematic review was performed to evaluate three primary outcomes: efficacy; immunogenicity; and safety of vaccines in children with chronic conditions treated with biologics.MethodsThe protocol for our systematic review and meta-analysis was registered and published with PROSPERO. We searched electronic bibliographic databases for studies published from 2009 to 2019, focusing on vaccinations in children with chronic conditions treated with biologics.ResultsWe retrieved 532 records. Thirty-one full-text articles were selected, and 14 were included in the meta-analysis. No significant publication bias was found. Efficacy: limited data are available regarding the efficacy of vaccination, as most studies have focused on immunogenicity as surrogate outcome for efficacy. Immunogenicity: patients receiving anti-TNF-alpha therapy had a statistically significant risk of poor seroconversion (p = 0.028) and seroprotection by the serotype B influenza vaccine [inflammatory bowel disease (IBD) p = 0.013; juvenile idiopathic arthritis (JIA) p = 0.004]. We found adequate responses with H1N1 and H3N2 serotypes. Few studies existed for pneumococcal, hepatitis A virus, hepatitis B virus, varicella-zoster virus, Measles Mumps Rubella virus, and multiple vaccine administration. Safety: vaccine administration was not associated with serious side effects, but JIA patients on anti-TNF alpha therapy had a statistically significant risk of presenting with myalgia or arthralgia postinfluenza vaccine (p = 0.014).ConclusionsMore evidence concerning efficacy, immunogenicity, and safety of vaccinations is needed to guide physicians in the vaccine decision process for this pediatric population. 相似文献
5.
6.
7.
8.
《Vaccine》2022,40(49):7151-7157
IntroductionRespiratory Syncytial Virus (RSV) is a major cause of acute lower respiratory tract infections (ALRI) in infants. There are no licensed vaccines and only one monoclonal antibody available to protect infants from disease. A new and potentially longer-lasting monoclonal antibody, Nirsevimab, showed promising results in phase IIb/III trials. We evaluate the cost-effectiveness of Nirsevimab intervention programmes in England and Wales.MethodsWe used a dynamic model for RSV transmission, calibrated to data from England and Wales. We considered a suite of potential Nirsevimab programmes, including administration to all neonates (year-round); only neonates born during the RSV season (seasonal); or neonates born during the RSV season plus infants less than six months old before the start of the RSV season (seasonal + catch-up).ResultsIf administered seasonally to all infants at birth, we found that Nirsevimab would have to be priced at £63 or less per dose for at least 50% certainty that it could cost-effectively replace the current Palivizumab programme, using an ICER threshold of £20,000/QALY. An extended seasonal programme which includes a pre-season catch-up becomes the optimal strategy at a purchasing price of £32/dose or less for at least 50% certainty. At a purchasing price per dose of £5-32, the annual implementation costs of a seasonal programme could be as high as £2 million before a switch to a year-round strategy would be optimal.DiscussionNirsevimab has the potential to be cost-effective in England and Wales not only for use in high-risk infants. 相似文献
9.
《European journal of surgical oncology》2022,48(6):1264-1271
BackgroundIn order to avoid excessive treatment of thyroid nodules in the clinic, it is necessary to find a simple and practical analysis method to comprehensively and accurately reflect benign or malignant thyroid nodules. This study aimed to construct and validate a comprehensive and reliable network-based predictive model using a variety of imaging and laboratory criteria for thyroid nodules to stratify the risk of malignancy prior to surgery.MethodsWe retrospectively analyzed data from patients who underwent surgical treatment for thyroid nodules at the Thyroid and Breast Diagnosis and Treatment Center of Weifang Hospital of Traditional Chinese Medicine between January 2018 and December 2020. Binary logical regression analysis was performed to predict whether nodules were malignant or benign. The developmental dataset included 457 patients (January 2018–December 2020). The validation set included separate data points (n = 225, January 2018–December 2020).ResultsIn this study, criteria that showed significant predictive value for malignant nodules included TI-RADS: 4b (p = 0.065); Bethesda IV, Bethesda V, Bethesda VI (P < 0.0001); BRAFV600E mutation (P < 0.0001); Calcitonin>5 pg/ml (p = 0.0037); and FNA-Tg>30 ng/ml (p = 0.0003). A 10-grade risk scoring system was developed. The risk of malignancy risk ranged from 2.06% to 100% and was positively associated with increasing risk grade. The areas under the receiver-operating characteristic curve of the development and validation sets were 0.972 and 0.946, respectively.ConclusionA simple, comprehensive and reliable web-based predictive model was designed using a variety of imaging and laboratory criteria to stratify thyroid nodules by probability of malignancy. 相似文献
10.